Xue Shuyu, Zeng Hanqiao, Yan Shu, Wang Qianmeng, Jia Xiaojing
Department of Tumor Radiotherapy, The Second Hospital of Jilin University, Changchun, China.
Front Oncol. 2022 Feb 7;12:772282. doi: 10.3389/fonc.2022.772282. eCollection 2022.
Small-cell lung cancer (SCLC) is a highly aggressive malignant tumor that is prone to lead to the development of brain metastases (BM). The application of prophylactic cranial irradiation (PCI) has been regarded as an important technological advance made in cancer therapy to reduce the occurrence of BM and improve patient survival. The benefits of PCI in the treatment of limited-stage SCLC have been confirmed. However, there has been continuous controversy about the indications and advantages of PCI for extensive-stage SCLC (ES-SCLC) because of the conflicting results from two prospective trials. In this review, we aimed to discuss the relevant controversy and progress made in the clinical application of PCI in ES-SCLC.
小细胞肺癌（SCLC）是一种极具侵袭性的恶性肿瘤，容易导致脑转移（BM）的发生。预防性颅脑照射（PCI）的应用被视为癌症治疗中取得的一项重要技术进步，可减少BM的发生并提高患者生存率。PCI在局限期SCLC治疗中的益处已得到证实。然而，由于两项前瞻性试验结果相互矛盾，对于广泛期SCLC（ES-SCLC）患者PCI的适应证和优势一直存在争议。在本综述中，我们旨在探讨ES-SCLC患者PCI临床应用中的相关争议和进展。
